[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483410":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":50,"collaborators":10,"id":52,"slug":10,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":65,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ovarian cancer patients",null,"Newly diagnosed patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer",[13],"Other: Standard of care",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Standard of care","Patients receive standard of care treatment according to local and national guidelines",[9],[20],{"name":21,"affiliation":22,"role":23},"Mansoor R Mirza, MD","NSGO-CTU","STUDY_CHAIR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Kristine Madsen, MD","CONTACT","004535453311","kristine.madsen.01@regionh.dk",{"name":31,"role":27,"phone":28,"phoneExt":10,"email":32},"Henriette W Hansen, MSc","henriette.watson.hansen@regionh.dk",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":10,"geoPoint":10,"contacts":42},"Rigshospitalet","RECRUITING","København Ø","Region Sjælland","2100","Denmark","DK",[43,47],{"name":44,"role":27,"phone":45,"phoneExt":10,"email":46},"Mansoor Raza Mirza","4535459624","mansoor@rh.regionh.dk",{"name":48,"role":27,"phone":49,"phoneExt":10,"email":29},"Kristine Madsen","35453372",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100483410",false,"NCT05574673","Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype","Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype - A Prospective Observational Study","HERO","Patients are eligible to be included in the study, if all the following inclusion criteria are met:\n\n* Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:\n\n  * FIGO stage I-II with a known BRCA1\u002F2 mutation (germline\u002FgBRCA or somatic\u002FtBRCA)\n  * FIGO stage III-IV of any histology\n* Women aged ≥18 years of age at the time of diagnosis\n* Patients intended for platinum-based chemotherapy treatment\n* Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\n* Patients consent to provide archival tumor tissue sample\n\nPatients are ineligible to be included in the study, if any of the exclusion criteria are met:\n\n* Non-epithelial ovarian cancer, borderline tumors, or mucinous histology\n* Patients with FIGO stage I-II, BRCAwt ovarian cancer","FEMALE","18 Years","100 Years",{"count":63,"type":64},1000,"ESTIMATED","5 Years","OBSERVATIONAL","This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1\u002F2 and HRD status.",[69,70,71],"Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer",[73],"Ovarian cancer, observational study, HRD","2026-02-24",{"date":76,"type":77},"2026-02-27","ACTUAL",{"date":79,"type":77},"2022-12-01",{"date":81,"type":64},"2032-07-01",{"name":5,"class":6},1]